ENLIVEN THERAPEUTICS, INC. Debt Securities, Available-for-sale, Current
ENLIVEN THERAPEUTICS, INC. (ELVN) had Debt Securities, Available-for-sale, Current of $6.81 million as of 2022-09-30, per its 10-Q filed 2022-10-25.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent · last filed 2023-02-10
- 2022-09-30: Debt Securities, Available-for-sale, Current $6.81M.
- 2022-06-30: Debt Securities, Available-for-sale, Current $29.91M.
- 2022-03-31: Debt Securities, Available-for-sale, Current $36.42M.
- 2021-12-31: Debt Securities, Available-for-sale, Current $41.97M.
| Period end | Debt Securities, Available-for-sale, Current |
|---|---|
| 2022-09-30 | $6.81M 10-Q · filed 2022-10-25 |
| 2022-06-30 | $29.91M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $36.42M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $41.97M 10-K · filed 2023-02-10 |
| 2021-09-30 | $27.54M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $18.73M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $22.15M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $40.52M 10-K · filed 2022-03-15 |
| 2020-09-30 | $61.93M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $51.62M 10-Q · filed 2020-08-14 |
| 2020-03-31 | $19.14M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $23.97M 10-K · filed 2021-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |